Статья
КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ОСТЕОПОРОЗА ПРИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
Статья посвящена проблеме нарушенного костного метаболизма у больных с хронической сердечной недостаточностью. Представлены актуальность проблемы, встречаемость остеопороза, патофизиологические механизмы нарушения костного метаболизма и общие факторы риска развития сердечной недостаточности и остеопороза. Описывается тактика ведения больных с сердечной недостаточностью и остеопорозом.
1. Keen R. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003; 1:66–70.
2. Lesnyak O. M. Audit of the problem of osteoporosis in the Russian Federation. Preventive Medicine 2011; 2:7–10. Russian (Лесняк О. М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина 2011; 2:7–10).
3. Cowie M., Fox K., Wood D. et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002; 23:877–85.
4. Inglis S., Clark R., Shakib S. et al. Hot summers and heart failure: Seasonal variations in morbidity and mortality in Australian heart failure patients (1994–2005). Eur J Heart Fail 2008; 10:540–9.
5. Mareev V. Y., Ageev F. T., Arutyunov G. P. et al. National guidelines of RSSC and OSSN and the diagnosis and treatment of chronic heart failure (third revision). J Heart Fail 2010; 1 (57):3–63. Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). ЖСН 2010; 1 (57):3–63).
6. Aronow W. Heart disease and aging. Med Clin North Am 2006; 90:849–62.
7. Jankowska E., Jakubaszko J., Cwynar A. et al. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 2009; 11:28–38
8. Storozhakov G. I., Ganieva I. I., Resnick E. V. et al. The relationship of
9. osteoporosis and cardiovascular system. Russ J Med 2011; 3:34–41. Russian (Сторожаков Г. И., Ганиева И. И., Резник Е. В. и др. Взаимосвязь остеопороза и заболеваний сердечно-сосудистой системы. РМЖ 2011; 3:34–41).
10. Pronchenko I. A., Koliashvili T. K., Buzulina V. P. et al. The state of bone
11. turnover and its regulation in potential recipients of donor hearts. Bulletin
12. of Transplantation and Artificial Organs 2009; 1 (XI); 46–51. Russian
13. (Пронченко И. А., Колиашвили Т. К., Бузулина В. П. и др. Состояние обмена костной ткани и его регуляции у потенциальных реципиентов донорского сердца. Вестник трансплантологии и искусственных органов 2009; 1 (XI); 46–51).
14. van Schoor N., Visser M., Pluijm S. et al. Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 2008; 42:260–6.
15. Majumdar S., Ezekowitz J., Lix L.et al. Heart failure is a clinically and
16. densitometrically independent risk factor for osteoporotic fractures:
17. population-based cohort study of 45,509 subjects. JCEM 2012; 97:1179–86.
18. Carbone L., Buzkova P., Fink H. et al. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 2010; 31 (1):77–84.
19. van Diepen S., Majumdar S., Bakal J. et al. Heart Failure Is a Risk Factor for Orthopedic Fracture. A population-based analysis of 16 294 patients. Circulation 2008; 118:1946–52.
20. Lyons K., Majumdar S., Ezekowitz J. The unrecognized burden of osteoporosisrelated vertebral fractures in patients with heart failure. Circ Heart Fail 2011; 4:419–24.
21. Frost R., Sonne C., Wehr U., Stempfle H. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 2007; 156:309–14.
22. Lesnyak O. M., Benevolenskaya L. I. Osteoporosis. Diagnosis, prevention and treatment. Clinical recommendations. Moscow. 2009; GEOTAR Media. P.270. Russian (Лесняк О. М., Беневоленская Л. И. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Москва 2009; Гэотар-Медиа. С.270).
23. Crotti T., Smith M., Findlay D. et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004; 25:565–73.
24. Kharchenko E. P. Heart failure: pathogenetic continuum and biomarkers. Cardiology 2012, 3:53–63. Russian (Харченко Е. П. Сердечная недостаточность: патогенетический континуум и биомаркеры. Кардиология 2012; 3:53–63).
25. Ermakov I. P., Pronchenko I. P. Osteoporosis after cardiac transplantation. In. Heart transplantation. Ed. Shumakov V. I. Moscow. Medical Information Agency; 2006; Chapter 23. P. 357–368. Russian (Ермакова И. П., Пронченко И. А. Остеопороз после трансплантации сердца. В кн. Трансплантация сердца. Под ред. В. И. Шумакова. М.: Медицинское информационное агентство; 2006; Глава 23. С. 357–68).
26. Schett G., Kiechl S., Redlich K. et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004; 291 (9):1108–13.
27. Demer L., Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117:2938–48.
28. Jankowska E., Haehling S., Czarny A. et al. Activation of the NF-kB system in peripheral blood leucocytes from patients with chronic heart failure. Eur J Heart Fail 2005; 7:984–90.
29. Tanko L., Christiansen C., Cox D. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20:1912–20.
30. Chhokar V., Sun Y., Bhattacharya S. et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005; 111:871–8.
31. Pepe J., Romagnoli E., Nofroni I. et al. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 2005; 16:805–12.
32. Kenny A., Boxer R., Walsh S. et al. Femoral bone mineral density in patients with heart failure. Osteoporos Int 2006; 17:1420–7.
33. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477–501.
34. Terrovitis J., Zotos P., Kaldar E. et al. Bone mass loss in chronic heart
35. failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail 2012; 1:326–32.
36. Fall T., Shiue I. Geijerstam B. et al. Relations of circulating vitamin D
37. concentrations with left ventricular geometry and function. Eur J Heart Fail
38. ; 14 (9):985–91.
39. Ameri P., Ronco D., Casu M. et al. High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis 2010; 20:633–40.
40. Liu L., Voors A., van Velhuisen D. et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail 2011; 13:619–25.
41. Schierbeck L., Jensen T., Bang U. et al. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011; 13:626–32.
42. Bouillon R., Carmeliet G., Verlinden L. еt al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29:726–76.
43. Li Y., Kong J., Wei M. et al. 1,25-Dihydroxyvitamin D (3) is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest 2002; 110:229–38.
44. Artaza J., Mehrotra R., Norris K. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol 2009; 4:1515–22.
45. Dukas L., Schacht E., Runge M.: Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall–related fractures in elderly men and women diagnosed with osteoporosis. Osteoporosis International 2010; 7 (21):1237–45.
46. Hillege H., Hitsch D., Pfeffer M. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 7: 113 (5):671–8.
47. Psarrasl S., Mavroidisl M., Sanoudou D. et al. Regulation of adverse
48. remodelling by osteopontin in a genetic heart failure model. Eur Heart J 2012; 33 (15):1954–63.
49. Kanis J., Johnell O., Oden A. et al. FRAXtm and the assessment of fracture probability in men and women from the UK. Osteoporosis Int 2008; 19 (4):385–97.
50. Epstein S., Stuss M. Transplantation osteoporosis. Polish Journal of Endocrinology 2011; 62 (5):472–85.
51. Lesnyak O. M., Benevolenskaya L. I. Osteoporosis. 2nd edition, revised and add. (Series “guideline”). M. GEOTAR Media 2011; P.272. Russian (Лесняк О. М., Беневоленская Л. И. Остеопороз. 2-е издание, перераб. и доп. (Серия “Клинические рекомендации»). М.: ГЭОТАР-Медиа 2011; 272 С.).
52. Law P., Sun Y., Bhattacharya S. et al. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 2005; 46:142–6.
53. Carbone L., Cross J., Raza S. et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol 2008; 52:135–8.
54. Lynn H., Kwok T., Wong S. et al. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese Bone 2006; 38:584–8.
55. Rickard D., Wang F., Rodriguez-Rojas A. et al. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006; 39:1361–72.
56. Lippuner K. The future of osteoporosis treatment – a research update. Swiss Med Wkly 2012; 142.
57. Cummings S., San Martin J., McClung M. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756–65.
58. Rachner T., Khosla S., Hofbauer L. Osteoporosis: now and the future. Lancet 2011; 377 (9773):1276–87.
59. Seibel M. Biochemical markers of bone turnover Part I: biochemistry and variability. Clin Biochem Rev 2005; 26 (4):97–122.